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Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of the women of reproductive age. Familial clustering
of PCOS has been consistently reported suggesting that genetic factors play a role in the development of the syndrome although
PCOS cases do not exhibit a clear pattern of Mendelian inheritance. It is now well established that PCOS represents a complex trait
similar to type-2 diabetes and obesity, and that both inherited and environmental factors contribute to the PCOS pathogenesis. A
large number of functional candidate genes have been tested for association or linkage with PCOS phenotypes with more negative
than positive ﬁndings. Lack of universally accepted diagnostic criteria, diﬃculties in the assignment of male phenotype, obscurity
in the mode of inheritance, and particularly small sample size of the study populations appear to be major limitations for the
genetic studies of PCOS. In the near future, utilizing the genome-wide scan approach and the HapMap project will provide a
stronger potential for the genetic analysis of the syndrome.
Copyright © 2007 Ugur Unluturk et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
PCOS is a highly prevalent endocrine disorder aﬀecting ap-
proximately 7% of reproductive-aged women [1]. There is
no consensus on the diagnostic criteria and deﬁnition of
PCOS.Themostwidelyused1990NationalInstituteofChild
Health and Human Development (NICHD) conference di-
agnostic criteria include (i) clinical and/or biochemical signs
of hyperandrogenism, (ii) oligo-ovulation, and (iii) exclu-
sion of other known disorders such as Cushing’s syndrome,
hyperprolactinemia and nonclassic adrenal hyperplasia [2].
A recent expert meeting sponsored by European Society of
Human Reproduction and Embryology (ESHRE)/American
Society for Reproductive Medicine (ASRM) suggested that
the deﬁnition of PCOS should include two of the follow-
ing three criteria: (i) oligo- and/or anovulation, (ii) clinical
and/or biochemical signs of hyperandrogenism, (iii) poly-
cystic ovaries on ultrasonography, and exclusion of related
disorders [3, 4].
Patients with PCOS have several interrelated characteris-
tics including hyperandrogenism, altered gonadotropin dy-
namics, chronic anovulation, polycystic ovaries, and insulin
resistance. The syndrome has a signiﬁcant reproductive and
metabolic impact, and is associated with increased risk of
type-2 diabetes, dyslipidemia, cardiovascular disease (CVD),
and endometrial carcinoma [5–7]. Overall, PCOS can be
viewed as a heterogeneous androgen excess disorder with
varying degrees of gonadotropic and metabolic abnormali-
ties. Development of PCOS may require the interaction of
multiple inherited and environmental factors. Herein, we
will brieﬂy overview the available evidence regarding the ge-
netic basis of PCOS.
2. FAMILIAL AGGREGATION OF THE SYNDROME
The familial aggregation of PCOS phenotypes and of asso-
ciated metabolic and reproductive abnormalities has been
long noted [8]. While clustering of cases in families strongly
support the role of genetic factors in the development of
PCOS,heterogeneityofphenotypic featuresindiﬀerent fam-
ilies and even within the same family underscores the impor-
tance of the environmental contribution. PCOS appears to
be a common and complex trait and the exact pattern of in-
heritance is yet to be fully explained [22, 23]. Family stud-
ies of PCOS investigated mainly ovarian morphology, men-
strual irregularities, symptoms of hyperandrogenism and2 PPAR Research
Table 1: Summary of the studies of familial aggregation in PCOS.
Suggested inheritance Diagnostic criteria Phenotype in
ﬁrst-degree relatives References
Autosomal dominant with
variable penetrance
Oligomenorrhea, hirsutism,
and (a)PCO
Women: oligomenorrhea
and PCO
Cooper et al. [8]
X-linked Oligomenorrhea, hirsutism,
and PCO
Women: hyperandrogenism
and metabolic disorders
Men: oligospermia
and LH hypersecretion
Givens et al. [9, 10]
Not determined Hirsutism and/or
oligomenorrhea
Women: infertility,
oligomenorrhea,
and hirsutism
Ferriman and Purdie [11]
Autosomal dominant
Menstrual dysfunction,
hyperandrogenism, obesity,
infertility, and PCO
Women: hyperandrogenic
symptoms
Men: premature baldness
and increased hairiness
Lunde et al. [12]
Not determined
Menstrual irregularities,
hirsutism, infertility,
PCO, and obesity
Women:P C O H a g u ee ta l .[ 13]
Monogenic PCO Women:P C O
Men: premature baldness Carey et al. [14]
Not determined Elevated androgens,
decreased SHBG, and PCO
Men: premature baldness,
hypertriglyceridemia,
and hyperinsulinemia
Norman et al. [15]
Not determined NICHD Women: Beta-cell dysfunction Colilla et al. [16]
Monogenic NICHD
Women: PCOS (NICHD),
hyperandrogenemia,
and insulin resistance
Legro et al. [17–19]
Not determined NICHD Women: PCOS (NICHD) Kahsar-Miller et al. [20]
Not determined NICHD
Women: PCOS (NICHD)
and insulin resistance
Men: insulin resistance
Yildiz et al. [21]
(a)PCO: polycystic ovaries.
hyperandrogenemia [11–14, 17, 20, 22, 24]. The results of
these studies are summarized in Table 1.
Cooper et al., in their large study, ﬁrst described that
the incidence of oligomenorrhea and polycystic ovaries is
increased in ﬁrst-degree relatives of PCOS patients com-
pared with the controls [8]. Although male relatives were not
speciﬁcally studied, a questionnaire revealed that they were
noted to have increased pilosity. Additionally, in this study
theproposedmechanismofinheritancewasautosomaldom-
inant with decreased penetrance [8].
Givens et al. have reported a series of family-based
studies, using as diagnostic criteria consisting of hirsutism,
oligomenorrhea,andenlargedovaries[9,10].Theyfoundfa-
milial aggregation of hyperandrogenic and metabolic disor-
ders. These studies were the ﬁrst to reveal some of the severe
metabolic sequelae, such as diabetes mellitus, insulin resis-
tance,lipidabnormalities,hypertension,andarteriosclerosis.
They also underscored the variability of phenotype in PCOS,
even within the same kindred. Oligospermia and increased
LH secretion were found in some of the male subjects of the
study participants, suggesting an X-linked pattern of inheri-
tance [9, 10].
Hague et al. utilized high-resolution ultrasonography to
identify polycystic ovaries in 61 women with menstrual dis-
turbances, hyperandrogenism, obesity, and infertility as well
as in their ﬁrst-degree female relatives [13]. They found that
67% of the mothers and 87% of the sisters of probands were
aﬀected [13]. In this study no attempt was made to identify a
male phenotype.
Ferriman and Purdie studied a large group of hirsute
women with and without oligomenorrhea and their fami-
lies [11]. They reported a higher prevalence of hirsutism,Ugur Unluturk et al. 3
oligomenorrhea and infertility in ﬁrst-degree relatives com-
pared with nonhirsute control women. A questionnaire re-
vealed an increased baldness in male relatives [11]. Aﬀected
female and male family members were not systematically
characterized in this study.
Lunde et al. studied families of 132 Norwegian women
identiﬁed on the basis of an ovarian wedge resection, who
also had two or more of the following symptoms: menstrual
irregularity, hirsutism, infertility, and/or obesity [12]. They
also compared these women with controls and their families,
and found a signiﬁcantly higher percentage of PCOS-related
symptoms in the ﬁrst-degree female relatives of PCOS pa-
tients and observed a signiﬁcantly higher percentage of pre-
mature balding and increased pilosity among male relatives
[12].
UsingNICHDcriteriaforthediagnosisofPCOS,Kahsar-
Milleretal.reportedtheratesofPCOSinmothersandsisters
of patients with PCOS as 24% and 32%, respectively [20].
Legro et al. showed that 22% of reproductive aged sisters of
women with PCOS fulﬁlled the diagnostic criteria of PCOS,
whereas 24% had increased T and DHEAS values with reg-
ular menstrual cycles [17]. We have reported 16% and 8%
PCOS prevalence rates in sisters and mothers of Turkish
PCOS patients, respectively [21].
Recently, quantitative phenotypes related to hyperandro-
genemia and glucose homeostasis are also shown to be heri-
table in PCOS. Evidence for heritability of metabolic pheno-
types such as beta cell function and insulin resistance was
reported in family studies of PCOS. Studying the families
of ﬁve patients with PCOS, Norman et al. reported that in-
creased insulin levels were common among ﬁrst-degree rel-
atives [15]. Colilla et al. noted that there was a heritable
component of beta cell dysfunction in families of women
with PCOS [16]. Legro et al. reported that aﬀected sis-
ters of women with PCOS (who fulﬁll criteria for the di-
agnosis of PCOS, and those with hyperandrogenemia) had
high insulin levels and low fasting glucose to insulin ratios
[18], and the brothers of women with PCOS had increased
dehydroepiandrosterone (DHEAS) levels [19]. We have re-
ported that mothers and fathers of PCOS patients have in-
creasedprevalenceofglucoseintoleranceandtype-2diabetes
whereas brothers and sisters show insulin resistance com-
pared to age- and BMI-matched healthy controls [21].
3. METHODS USED IN GENETIC STUDIES OF PCOS
Two mainstream approaches employed to identify a genetic
locus for PCOS are (i) association studies where a predispos-
ing allele is expected to be encountered more frequently in
the eﬀected population than the normal individuals and (ii)
linkage studies where the probands and their families are in-
vestigated to determine if particular genomic landmarks are
distributed independently or in linkage (together) with the
phenotype.Whilethemodeofinheritanceisnotrequiredfor
the association studies, it requires that a relatively large set of
individuals are needed for a clear conclusion. The canonical
linkage studies require that the mode of inheritance should
be known for the analysis procedure. These studies are quite
robust to identify single genes causing Mendelian disorders
but are poorly suited to the genetic architecture of complex
traitssuchasPCOS.Thevariablepenetranceandexpressivity
are two main factors that are complicating both association
and linkage methods (reviewed in [25]).
The frequency of the genomic landmarks used in link-
age studies deﬁnes the resolution and the mapping power
of the study. The whole genome scan approach utilizing
theSNP(single nucleotide polymorphism) microarraygene-
chiptechnologybringsthehighestresolutioningeneticmap-
ping [26]. Yet, there is no PCOS study published with this
technique. Furthermore the HapMap project brings further
power to association studies by genotyping over a million
SNPs and characterizing genetic variation patterns in linkage
disequilibrium [27].
4. CANDIDATE GENES IN PCOS
4.1. Genesinvolvedinovarianandadrenal
steroidogenesis
The most common biochemical abnormality in women with
PCOS is hyperandrogenemia (Figure 1). For this reason, re-
searchers have long been trying to ﬁnd a linkage or an associ-
ation between PCOS and the genes involved in the androgen
biosynthetic pathway. The most relevant genes involved in
steroidogenesis, CYP11a, CYP21, CYP17, and CYP19, along
with their controversial properties are discussed below.
4.1.1. CYP11a
Adrenal and ovarian steroidogenesis start with the conver-
sion of cholesterol into progesterone, which is catalyzed by
the P450 cytochrome side chain cleavage enzyme encoded
by CYP11a located at 15q24 [28]. This conversion is a rate
limiting step of steroidogenesis. Gharani et al. conducted
an association study of 97 women with PCOS and showed
a signiﬁcant association between serum testosterone levels
and the alleles of the CYP11a with a 5  untranslated region
(UTR) consisting of repeats of a (tttta)n pentanucleotide,
a VNTR (variable number tandem repeat) polymorphism
[29].Twoindependentcase-controlstudiesfromGreece[30]
and China [31], respectively, conﬁrmed these ﬁndings in
support of the encouraging evidence for the association be-
tween CYP11a and PCOS.
Although these studies proposed that allelic variants of
CYP11a have a role in the etiology of hyperandrogenemia
and/or PCOS, subsequent studies including one with a very
large sample size from United Kingdom and Finland [32]
havefailedtoﬁndasigniﬁcantlinkageorassociationbetween
this gene locus and/or its VNTR alleles and PCOS [32–36].
Above all, CYP11a, with its associated polymorphisms,
remains, at least in part, a potential candidate gene for the
pathogenesis of PCOS, and further investigations are re-
quired due to these controversial results.4 PPAR Research
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Figure 1: PCOS is a complex genetic syndrome. A dysregulation of androgen synthesis plays a key role in the pathogenesis of PCOS. This
dysregulation may be triggered by genomic variants related to hyperandrogenism and environmental factors, such as sedentary life-style and
dietary habits. The hyperandrogenemic condition causes follicles not to grow as much as dominant follicle and leads oligo/anovulation. The
progesterone peak does not occur through luteal phase of menstrual cycle, and the frequency and amplitude of GnRH pulses are increased,
which in turn cause the secretion of LH to increase. By means of increasing LH levels, androgen synthesis and secretion are stimulated in
the ovaries and adrenals. On the other hand, the inherited insulin resistance leads a hyperinsulinemic condition causing androgen synthesis
to increase and SHBG synthesis to decrease. Additionally, obesity that is inherited and/or acquired could cause a chronic inﬂammation via
secretinginﬂammatorycytokinesfromadiposetissue,whichstimulatesandrogensythesisandincreasesinsulinresistance.Asaconsequence,
interactions among ovary, hypothalamus-pituitary, adrenal, adipose tissue, liver, skeletal muscle and  β-cells of pancreas draw the picture of
PCOS. Environmental factors and genetic variations constitute the phenotypic variability/colors of the picture.
4.1.2. CYP21
One of the main steps in adrenal and ovarian steroido-
genesis is the conversion of 17-hydroxyprogesterone into
11-deoxycortisol, which is catalyzed by the 21-hydroxylase
enzyme encoded by CYP21. The deﬁciency of this en-
zyme, which is inherited by an autosomal recessive trait,
is responsible for most cases of congenital adrenal hyper-
plasia, and increased serum 17-hydroxyprogesterone levels
are correlated with its deﬁciency. Women with functional
hyperandrogenism or PCOS have an increased serum 17-
hydroxyprogesterone response to ACTH stimulation as a
commonﬁnding[37,38].Furthermore,patientshavingboth
heterozygote CYP21 mutations and clinical symptoms ex-
hibit a PCOS-like phenotype [39]. Accordingly, mutations of
CYP21 have been investigated as a candidate gene in patients
with PCOS. Witchel et al. showed that children with prema-
ture pubarche and adolescent girls with hyperandrogenism
were heterozygous for mutations in CYP21 [39, 40]. How-
ever, Escobar-Morreale et al. found no clear concordance
betweentheCYP21genotypeandthefunctionaloriginofan-
drogen excess [41] and Glintborg et al. could not ﬁnd such a
concordance in women with idiopathic hirsutism and PCOS
[42]. More recently, Witchel et al. conducted a case-control
study of 114 PCOS patients, which indicated no signiﬁcant
diﬀerences in the allele frequency of CYP21 mutations be-
tween PCOS patients with and without androgen excess and
controls[43].Overall,CYP21andassociatedmutationsseem
not to play a key role in the development of PCOS.
4.1.3. CYP17
Other rate limiting steps of adrenal and ovarian an-
drogen biosynthesis are the conversion of pregnenolone
and progesterone into 17-hydroxypregnenolone and 17-
hydroxyprogesterone, respectively, and of these steroids into
dehydro-epiandrosteroneandandrostenedione,whichiscat-
alyzed by the P450c17α enzyme. This enzyme has both
17α-hydroxylase and 17,20-lyase activities and is encodedUgur Unluturk et al. 5
by CYP17 located at 10q24.3 [44, 45]. It was initially pro-
posed that an exaggerated adrenal and ovarian responsive-
ness and increased P450c17α enzyme activity were responsi-
ble for enhanced androgen levels in patients with PCOS and
functional hyperandrogenism [46, 47]. Escobar-Morreale et
al. also suggested that most of the hyperandrogenic women
have increased P450c17α activity in adrenal and ovarian sites
[37, 48]. In accordance with these studies, Wickenheisser et
al. reported increased P450c17α expression and enzymatic
activityinovarianthecacellsfromwomenwithPCOSaswell
as increased transactivation of the CYP17 promoter [49, 50].
Moreover,theyreportedfortheﬁrsttimethatCYP17expres-
sion is dysregulated at the level of mRNA stability in PCOS
theca cells [51].
In another study, Carey et al. identiﬁed a rare T/C sin-
gle nucleotide polymorphism (SNP) in the promoter region
of CYP17 increasing the susceptibility to develop PCOS [52].
EventhoughDiamanti-Kandarakisetal.conﬁrmedthisﬁnd-
ing in Greek patients with PCOS [53], subsequent more
comprehensivestudieshavefailedtodetectasigniﬁcantlink-
age or association between CYP17 and PCOS [35, 54–58].
Although the available evidence suggests that CYP17 is
not a strong candidate gene for PCOS, we should also note
that posttranslational regulation of this gene product might
play a role in the pathophysiology of PCOS. Because serine
phosphorylation is involved in the posttranslational regula-
tion of 17,20-lyase activity [59], it was proposed that post-
transcriptional hyperphosphorylation of the serine residues
of P450c17α by a defective serine kinase might increase the
17,20-lyase activity of this enzyme [59, 60]. Interestingly,
it was demonstrated that serine phosphorylation of the β-
chain of the insulin receptor causes insulin resistance in vitro
[61, 62]. Another interesting ﬁnding is that 50% of PCOS
women who had both hyperandrogenism and insulin re-
sistance had hyperphosphorylated serine residues on their
insulin receptors [63]. Therefore, that a single defect pro-
duces both the insulin resistance and the hyperandrogenism
insomeofthePCOSwomenwaspostulated[64].Altogether,
these data provide an encouraging evidence to support the
serine kinase hypothesis of PCOS; however, this hypothesis
is still to be proved.
4.1.4. CYP19
An enzyme complex, called aromatase, converts C19 steroids
(androgens) to C18 steroids (estrogens). This enzyme com-
plex is composed of the cytochrome P450 aromatase
(P450arom) and the NADPH cytochrome P450 reductase
[65], and P450arom is encoded by CYP19 located at 15p21.1
[66, 67]. Aromatase deﬁciency has been reported in a num-
ber of hyperandrogenic patients [68, 69]. Immunohisto-
chemical studies of polycystic ovaries could not reveal any
aromatase activity in antral follicles of various sizes [70].
Erickson et al. demonstrated that granulosa cells obtained
from medium-sized follicles of women with PCOS have lit-
tle aromatase activity [71]. Similarly, Jakimiuk et al. showed
that when compared to the control follicles, all PCOS folli-
cles contained low levels of P450arom mRNA, estradiol, and
lower aromatase stimulating bioactivity [72]. These ﬁndings
indicate that the aromatase activity might be decreased in
follicles from patients with PCOS, and that the possible an-
drogen excess resulting from this decreased activity might
contribute to abnormal follicle development. Whether the
CYP19isacandidategeneforthepathogenesisofPCOSorof
hyperandrogenism has, therefore, been investigated. Linkage
and mutation screening studies did not reveal any evidence
that variation at the CYP19 locus participates in the etiology
of PCOS [29, 35, 73]. However, association studies utilizing
SNPs and haplotypes showed association with PCOS symp-
tom score and serum testosterone levels [74, 75].
4.2. Genesinvolvedinsteroidhormoneeffects
4.2.1. Androgenreceptorgene
All androgens operate through the androgen receptor and
this receptor belongs to a family of nuclear transcription fac-
tors. The androgen receptor is encoded by a gene (AR) lo-
cated at Xq11-12 [76] and is composed of three functional
domains: the transactivation domain, the DNA binding do-
main, and the ligand-binding domain. A VNTR polymor-
phism consisting of CAG repeats (from 11 to 38 repeats, an
average of 20) in exon-1, encoding a polyglutamine chain
in the N-terminal transactivation domain, is embedded in
AR [77]. The transcriptional activity of androgen receptor is
inversely correlated with the number of CAG repeats [78].
Variations of these repeats, even within the normal polymor-
phic range (11–38 CAGs), have been related to various disor-
ders associated with low- or high-androgenic activities [79–
82]. Therefore, decreased number of CAG repeats with an
increased androgen receptor activity could explain some of
the PCOS phenotype exhibiting the normal serum androgen
levels and hyperandrogenism symptoms [83]. Nevertheless,
Urbanek et al. could not ﬁnd any association between this
VNTR and PCOS [35]. Similarly, Mifsud et al. found no dif-
ferences between the anovulatory PCOS patients and con-
trols for the distribution of the CAG repeats [83]. On the
contrary, Hickey et al. demonstrated a signiﬁcantly greater
frequency of alleles with longer CAG repeats (> 22 repeats)
for infertile PCOS patients compared with fertile women
[84]. Indeed, both of these studies indicated an association
betweenthetestosteronelevelsandCAGrepeatsinAR,albeit
with diﬀerent results. Conﬁrming the reports of Urbanek et
al. [35]a n dM i f s u de ta l .[ 83], in a more recent study con-
ducted in Finland, J¨ a¨ askel¨ ainen et al. reported that CAG re-
peats of AR are not the major determinants of PCOS [85].
TheyalsofoundnocorrelationbetweenthisVNTRandbody
mass index or serum testosterone levels [85]. As a result, no
convincing evidence exists about the role of AR in the patho-
genesis of PCOS.
4.2.2. Sexhormone-bindingglobulingene
SHBG regulates the access of androgens to target tissues.
Serum SHBG levels are commonly low in patients with hy-
perandrogenism, especially in association with PCOS, which6 PPAR Research
contributes to increased tissue androgen availability [86].
Human SHBG is composed of a homodimeric glycoprotein
produced by hepatocytes and is encoded by a 4-kb gene
at the 17p12-p13 [87, 88]. A pentanucleotide repeat poly-
morphism, (TAAAA)n, at the promoter of human SHBG
gene has been described [89]. This polymorphism has also
been demonstrated to inﬂuence the transcriptional activ-
ity of SHBG gene [89]. Under the light of these data, it
has been proposed that this functional polymorphism could
contribute to individual diversities in plasma SHBG levels
and thus inﬂuence the access of androgens to target tissues
[90]. For this reason, Xita et al. investigated whether the
(TAAAA)n polymorphism of the SHBG gene is associated
with PCOS and whether polymorphic variants of the gene
arerelatedtoserumSHBGlevelsinwomenwithPCOS.They
reported a signiﬁcant association between this repeat poly-
morphism and PCOS in a Greek population [90]. In this
study, PCOS patients were frequently carrying more than 8
repeats while nonhyperandrogenic controls presented with a
higher frequency of alleles carried fewer than 8 repeats. Be-
sides, PCOSpatientscarrying thelongerallelegenotypeshad
lower SHBG levels [90]. In accordance with the latter result,
Cousin et al. recently demonstrated in hirsute women that
longer (TAAAA)n alleles caused serum SHBG levels to be de-
creasedwhencomparedwithsixrepeatalleles[91].Theyalso
identiﬁed that an SNP (Asp327Asn) in exon 8 of the SHBG
gene increases the SHBG half-life as well as having a strong
disequilibrium linkage with the eight (TAAAA)n polymor-
phism [91]. Although Urbanek et al. could not ﬁnd any asso-
ciation or linkage between a marker close to the SHBG locus
and PCOS [35], based on the available evidence it could be
concluded that SHBG gene is a potential candidate gene in
the pathogenesis of PCOS.
4.3. Genesinvolvedingonadotropinaction
andregulation
4.3.1. LHanditsreceptorgenes
BothincreasedLHlevelsandalteredLHactionarefrequently
observedinPCOSpatients,andtheseabnormalitiesareasso-
ciated with anovulation through, at least in part, an adverse
eﬀect of LH on oocyte maturation [92, 93]. Therefore, the
geneencodingtheβ-subunitofLH,responsibleforLHspeci-
ﬁcity, has been explored in PCOS patients.
Initially, an immunologically abnormal form of LH with
two-point mutations, Trp8Arg and Ilg15Thr, in the LH β-
subunit gene was identiﬁed [94]. Afterwards, it was demon-
strated that these mutations are universally common poly-
morphisms with 15% prevalence worldwide [95]. In addi-
tion, these mutations produced structural changes in the
variant LH molecules (v-LH) [96] and caused v-LH to have
an increased in vitro activity and a decreased in vivo half
life compared to that of nonmutant form [97]; however, in
vivo activity of v-LH could not be explained. In order to
understand the relevance of v-LH in patients with PCOS,
Rajkhowa et al. explored the implication of v-LH in both
healthywomenandPCOSpatientsandfoundthattheoccur-
renceofthesemutationsinLHβ-subunitgene wasnothigher
in PCOS compared with healthy women [98]. On the other
hand, subgroup analysis of this study revealed that obese
PCOS patients had a higher frequency of the heterozygous v-
LH compared with the obese controls [98]. Contrary to the
latter ﬁnding, Tapanainen et al. in their multicenter study re-
ported that the obese PCOS patients from the Netherlands,
Finland, and the United States, but not from the United
Kingdom have a lower frequency of this variant form [99].
Although this ﬁnding suggests that v-LH somehow protects
obese women from developing PCOS, other studies failed to
ﬁnd any association with PCOS [95, 100, 101].
Another identiﬁed variant form of LH was due to a sin-
gle missense mutation, Gly102Ser, in the LH β-subunit gene
[102]. Ramanujam et al. studied this mutation in 176 pa-
tients with menstrual disorders and 200 normal ovulatory
SingaporeChinesewomenandfounditpresentinonlyseven
patients with menstrual disorders [100]. Recently, Takahashi
et al. demonstrated that numerous SNPs in the promoter re-
gion of the LH β-subunit gene were more frequent in patients
with ovulatory disorders including PCOS than normal ovu-
latory women [103].
The hypothesis that an activating mutation in the LH
receptor gene might be a cause of hyperandrogenism in pa-
tients with PCOS having normal serum LH concentrations
and raised androgen levels was tested using linkage analy-
sis in families with multiple cases of PCOS, and ﬁve families
in whom polymorphic markers close to the LH receptor gene
segregatewiththesyndromewereidentiﬁed[104].Neverthe-
less, in a subsequent preliminary study, these authors did not
ﬁnd any mutations after gene sequencing in these aﬀected
families [104]. Likewise, Urbanek et al. reported negative re-
sults in their study in which total of 37 potential candidate
genes were examined in 150 families with PCOS [35].
In summary, the functional eﬀects of these v-LHs remain
unclear and seem not to play a key role in PCOS pathogen-
esis or female infertility, but further studies are required to
determine the physiological and pathophysiological signiﬁ-
cance of this LH variant.
4.3.2. Follistatingene
Follistatin, a monomeric glycoprotein encoded by a single
gene, is structurally unrelated to the TGF-β superfamily, but
is linked functionally through its role as a high-aﬃnity bind-
ing protein for activin [105]. Activin, a dimeric glycopro-
tein belonging to the TGF-β superfamily, induces FSH and
insulin secretion, ovarian follicular maturation and inhibits
LH-stimulated ovarian androgen production [105]. As an
activin-binding protein, follistatin can reverse each of these
activin-induced responses in vitro and in vivo [105–108].
Actually, overexpression of follistatin in transgenic mice re-
sulted in suppression of serum levels of FSH and arrested
ovarian folliculogenesis [106]. Excessive activin neutraliza-
tion due to increased follistatin may, therefore, reduce FSH
concentrations, arrest follicular maturation, increase andro-
gen production, and impair insulin release. Because all of
these changes are typical features of PCOS [109], follistatin
gene has been explored as a candidate gene in PCOS.Ugur Unluturk et al. 7
Initially, Urbanek et al. examined a total of 37 poten-
tial candidate genes in 150 families with PCOS, as men-
tioned above, and reported statistically signiﬁcant linkage
only between the follistatin gene and PCOS [35]. However,
subsequent more comprehensive follistatin gene studies con-
ducted by the same authors have not obtained any signiﬁ-
cant linkage [110]. In order to detect variation in the fol-
listatin gene, they made sequence analysis of this gene in
85 women of 19 families of PCOS patients and identiﬁed
sequence variants at 17 sites. Nevertheless, only one poly-
morphism of these sites was common, and in addition, the
site of this polymorphism was not translated [110]. They
also reported similar expression of the follistatin gene mRNA
in cultured ﬁbroblasts from PCOS and control women
[110]. Likewise, two studies including patients with PCOS
from Singapore [111]a n dS p a i n[ 112] could not ﬁnd any
signiﬁcant mutations in coding regions of the follistatin
gene.
4.4. Genesinvolvedininsulinactionandsecretion
Almost two decades ago, it was demonstrated that most
women with PCOS either obese or nonobese, compared
withnormalwomen,exhibitedvariabledegrees ofinsulinre-
sistance and compensatory hyperinsulinemia [113]. Subse-
quently convincing evidence has been started to accumulate,
andatpresent,itiswellknownthathyperinsulinemiaandin-
sulin resistance are common features of PCOS patients [64]
(Figure 1).Therefore,numerousgenesinvolvedininsulinac-
tion and secretion have been explored as candidate genes in
PCOSpathogenesis.Theinsulingene(INS),theinsulinrecep-
torgene(INSR),theinsulinreceptorsubstrategenes(IRSs)and
calpain-10 gene (CAPN10), the most relevant genes involved
ininsulinactionandsecretion,arediscussedbelowwiththeir
controversial results.
4.4.1. Theinsulingene
The INS is located between the genes for tyrosine hydrox-
ylase and for IGF-II at 11p15.5, and includes variable tan-
dem repeats (VNTR) embedded at the 5  regulatory region
of INS [114]. The VNTR polymorphism regulates the tran-
scriptional rate of the INS [115] and probably that of the
gene encoding IGF-II [116]. The number of the repeats of
the INS VNTR ranges from 26 to 200, and due to this feature
INS VNTR polymorphism has three size classes. Class-I al-
leles compose the shorter polymorphic region, consisting of
an average length of 40 repeats. Class-II alleles have an av-
erage length of 80 repeat units and are uncommon in Cau-
casian. Class-III alleles compose the longest polymorphic re-
gion having an average of 157 repeats [117]. Transcriptional
activity of the longer polymorphic region is greater than that
of the shorter one [115]. Besides their eﬀect on regulating
INS expression, they have been implicated in the pathogene-
s i so ft y p e - 2d i a b e t e sm e l l i t u si nm a n ys t u d i e s[ 118, 119].
It is not known whether the hyperinsulinemia detected
in PCOS is an outcome of primary insulin resistance or the
direct eﬀect of pancreatic β-cell disorder, whereas defects
in both insulin action [113, 120] and in pancreatic β-cell
function [121, 122] have been reported. Therefore, in or-
der to clarify the genetic basis of PCOS and to determine
its association with defects in insulin secretion and action,
ﬁrstly, Waterworth et al. evaluated the linkage and associa-
tion of the INS VNTR polymorphisms in families with af-
fected members with PCOS or male-pattern baldness [123].
They have found an association between PCOS and allelic
variation at the INS VNTR locus in three separate popula-
tions [123]. Furthermore, they found that class III alleles, es-
pecially the III/III genotypes, were associated with anovula-
tory PCOS in two independent populations and were more
frequent among women with polycystic ovaries with symp-
toms than those without symptoms [123]. In addition, in
the same study, it was shown that the geometric mean of
fasting serum insulin concentrations was signiﬁcantly higher
in families with evidence of linkage than in families with
no evidence of linkage [123]. These data support the idea
that the VNTR polymorphisms have a functional role on
the establishment of hyperinsulinemia and/or insulin resis-
tance component phenotypes in PCOS. The same group also
reported that class III alleles were transmitted signiﬁcantly
more common from fathers than from mothers to aﬀected
daughter, suggesting a “parent of origin” eﬀect in the trans-
mission of alleles [123]. The latter ﬁnding was conﬁrmed by
Eaves et al. [124]. In support of this evidence, Michelmore
et al. demonstrated that class III alleles, III/III genotype,
and paternal class III allele transmissions were signiﬁ-
cantly related to increased number of PCOS features and
to reduced insulin sensitivity among women with PCOS
[125].
In a more comprehensive study, however, Urbanek et al.
could not ﬁnd any evidence for the linkage of INS and PCOS
and for the association of the class III allele and of hyper-
androgenemia [35]. But the diﬀerence of this study from
other previous studies where the ultrasonographic ﬁndings
were more commonly used was that the NIHCD selection
criteria were used. Likewise, Calvo et al. studied the INS
VNTR polymorphisms in Spanish women with hyperan-
drogenemia and failed to show any association compared
to the controls [126]. Similarly, Vankov´ a et al. studied the
association of INS VNTR polymorphisms with PCOS in
Czech women and failed to ﬁnd any association relevant
to VNTR and PCOS [127]. Using diﬀerent selection crite-
ria, studying patients with variable ethnic and geographical
backgrounds, selection bias, and most importantly working
with small to, at best, modest sample sizes might explain
the presence of these conﬂicting results. Consistently, study-
ing associations with a small sample size is known to be a
major risk factor for the generation of results that cannot
be replicated on consecutive examinations [128]. As a so-
lution to this problem, more recently, Powell et al. rebut-
ted the relationship between the INS VNTR and PCOS, us-
ing several complementary analytical approaches, including
case-control, family-based, and quantitative trait association
methods in more than 3500 subjects from United Kingdom
and Finland [129].8 PPAR Research
4.4.2. INSR
The insulin receptor is a heterotetrameric glycoprotein com-
posed of two α and two β-subunits and is encoded by the
INSR located at the chromosome 19 [130]. Several studies
were conducted to identify whether the mutations of INSR
could explain insulin resistance in women with PCOS. Ini-
tially,directsequencingofINSRfromtwoobesewomenwith
PCOS did not reveal any mutations [131]. Consequently,
Conway et al. [132] analyzed the sequence of the tyrosine
kinase domain of INSR in 22 hyperinsulinemic patients with
PCOS and Talbot et al. [133] investigated the mutations by
molecular scanning of the entire coding region of INS in
24 hyperinsulinemic women with PCOS, and none of these
groups detected any signiﬁcant mutations related to insulin
resistance in PCOS [133]. In addition, Urbanek et al., using
thedinucleotiderepeatmarker,D19S884,foundevidencefor
theassociationoftheINSRwithPCOSintheirTDTanalysis,
but after correction for multiple testing, this ﬁnding lost its
statistical signiﬁcance [35]. However, using the same marker,
Tucci et al. proved the association with INSR in women with
PCOS [134]. Nevertheless, this association could not be con-
ﬁrmed in a consecutive study from the Mediterranean area
[135]. More recently, a comprehensive study published by
Urbanek et al. demonstrated a linkage with PCOS in a group
of well-characterized 367 families including individuals pre-
dominantly of European origin with PCOS [136]. A broad
region of the chromosome 19p13.2 was investigated and the
strongest evidence for association was found with D19S884,
supporting the previous ﬁndings by these authors [136].
In another study, Siegel et al. examined an SNP at the ty-
rosine kinase domain of INSR and found an association in
lean patients with PCOS. This SNP could be a susceptibility
variant for PCOS, or it can be a result of linkage disequilib-
rium with another INSR polymorphism, but the association
is pending conﬁrmation [137].
4.4.3. Insulinreceptorsubstrateproteins
Activation of the insulin receptor following insulin binding
requires the autophosphorylation of the β-subunit of the in-
sulin receptor [138]. The consequent tyrosine kinase activity
generated after autophosphorylation phosphorylates insulin
receptor substrates (IRS), such as IRS-1 and IRS-2 [64]. Af-
terwards, IRS-1 and IRS-2 bind and activate downstream ef-
fectors, such as phosphoinositide 3-kinase, to promote the
metabolic and mitogenic actions of insulin. When IRS-1 is
dysfunctional,IRS-2isthemainmessengerfortheintracellu-
lar transmission of the insulin signal, but it requires a higher
insulin concentration for activation [139].
Several polymorphisms of IRS1 and IRS2 genes (IRS1
and IRS2) have been implicated in insulin resistance. The
Gly972Arg polymorphism for IRS-1 and Gly1057Asp for
IRS-2 have been shown to increase susceptibility to type-2
diabetes mellitus [140, 141]. Although initially no evidence
for linkage or association with PCOS was found with IRS-
1 in a family-based study conducted by Urbanek et al. [35],
the potential roles of these SNPs of IRS genes in insulin resis-
tancehavefurtherbeeninvestigatedinPCOS.Sir-Petermann
et al. reported a higher frequency of the Arg972 IRS-1 al-
lele in PCOS patients in Chilean population [142]. Con-
trary to this report, El Mkadem et al. could not ﬁnd any
diﬀerences in the distribution of IRS-1 Gly972Arg and IRS-
2 Gly1057Asp alleles in PCOS patients and controls; how-
ever, they demonstrated that the Gly972Arg IRS-1 was more
prevalent in insulin-resistant patients compared with the
noninsulin resistant patients or control subjects [143]. Be-
sides, they showed gene-dosage eﬀects on fasting insulin
levels for Gly972Arg IRS-1 a n do n2 - hp l a s m ag l u c o s el e v e l s
during oral glucose tolerance test (OGTT) for Gly1057Asp
IRS-2 in women with PCOS, while no novel mutations
have been found in these genes by direct sequencing [143].
Ehrmann et al. investigated the inﬂuences of Gly972Arg
IRS-1 and of Gly1057Asp IRS-2 polymorphisms in nondi-
abetic women with PCOS [144]. Although the IRS-1 geno-
type was not found to be associated with any clinical or hor-
monalmeasuresinnondiabeticPCOSsubjects,carryingIRS-
2 Gly/Gly genotype was associated with signiﬁcantly higher
glucose levels in 2-h OGTT compared with carrying Gly/Asp
and Asp/Asp genotypes [144]. In this study, the association
of Gly/Asp genotype with lower glucose levels during 2-h
OGTT [144] was just contrary to the report of El Mkadem
et al. [143]. Conﬁrming the report of El Mkadem et al. [143],
Villuendas et al. showed that these polymorphisms had an
equal distribution pattern among PCOS patients and con-
trols from Spain [145]. These investigators also found that
carrying the Arg972 allele for IRS-1 and carrying the ho-
mozygous Gly1057 for IRS-2 present negative eﬀects on glu-
cose homeostasis compared with carrying the homozygous
Gly972 alleles for IRS-1 and one or two Asp1057 alleles for
IRS-2,r e s p e c t i v e l y[ 145].
I nar e c e n ts t u d y ,D i l e ke ta l .r e p o r t e dah i g h e rf r e -
quency of the Gly972Arg polymorphism for IRS-1 in Turk-
ish women with PCOS [146] in accordance with the data of
Sir-Petermann et al. [142]. Moreover, similar to the data ob-
tained by El Mkadem et al. [143] and Villuendas et al. [145],
they found that the Gly972Arg carriers were more obese,
more insulin-resistant and had higher fasting insulin lev-
els when compared with the other PCOS patients and con-
trols [146]. These investigators also studied the same Turkish
PCOS patients for the potential diﬀerential eﬀects of met-
formin therapy on the basis of IRS-1 genotype [147]. In
this study, metformin lowered the LH, DHEAS, total testos-
terone, and fasting insulin levels and decreased insulin re-
sistance and free testosterone index in Gly972Arg-negative
PCOS women more eﬀectively and signiﬁcantly when com-
paredwiththeGly972Arg-positivewomen[147].Theseﬁnd-
ings could be taken as an indirect indicator of the relation-
ship between the IRS-1 genotype and the insulin resistance
phenotype of PCOS. Interestingly, some of the proposed
mechanisms for the action of metformin at cellular level
are that it might augment the tyrosine phosphorylation of
the insulin receptor β-subunit and IRS proteins and also in-
creasetheinsulin-dependentandnondependentcellularglu-
cose uptake through the family of glucose transporter pro-
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hypothesized that variant IRS-1 proteins might not be able
to transmit signals and thus might not be able to increase the
glucose uptake into the muscle and adipose cells [147]. This
hypothesismay,atleastinpart,beanexplanationoftheasso-
ciation of IRS-1 genotype with insulin resistance in some of
PCOS patients; however these data are yet to be conﬁrmed.
Overall, the association studies of IRSs with PCOS and
insulin resistance phenotype of this syndrome exhibit many
conﬂicting properties as seen with the other candidate genes
for PCOS. We should emphasize however that these IRS
polymorphisms seem to be associated separately with insulin
resistanceratherthanPCOSinthesestudies.Therefore,more
comprehensive studies are required to solve the puzzle of re-
lations among these genes and PCOS.
4.4.4. Calpain10gene
Calpain-10 is a cysteine protease that plays a role in insulin
secretion and action [149], and genetic studies have shown
that variation in the gene (CAPN10) encoding calpain-10
is associated with type-2 diabetes [150]. Due to the fact
that PCOS and type-2 diabetes share a number of etio-
logic factors [64, 151], Ehrmann et al. sought to determine
whether variation in the CAPN10 is associated with quanti-
tative traits related to the pathogenesis of PCOS and type-
2 diabetes [152]. They found an association between the
112/121 haplotype of this gene and higher insulin levels in
African-American women and an increased risk of PCOS
in both African-American and white women [152]. Gon-
zales et al. investigated whether four SNPs (SNP-19, SNP-
43, SNP-44, and SNP-63) of the CAPN10 were associated
with PCOS [153, 154]. In support of the latter, they reported
in their consecutive studies that SNP-44 of the gene is as-
sociated with PCOS in Spanish women [153, 154]. Never-
theless, using the same four SNPs, Haddad et al. could not
conﬁrm any association with PCOS in a more comprehen-
sive study [155]. Likewise, Escobar-Morreale et al. studied
three SNPs (SNP-43, SNP-44, and SNP-45) of CAPN10 and
reported no association between any of those and PCOS
[156]. These conﬂicting results suggest that deﬁnitive con-
clusions could only be drawn by studying larger populations
probably including thousands rather than hundreds of sub-
jects.
4.5. Genesinvolvedinenergyhomeostasisandthe
relevanceofperoxisomeproliferator-activated
receptor-γ gene
4.5.1. Thegenesofleptin,leptinreceptor,andadiponectin
Although the adipose tissue has long been regarded as an in-
ert and passive type of connective tissue that stores and re-
leases energy, during the last decade it has been recognized
that the adipose tissue is not only a connective tissue but is
also one of the active endocrine organs which secretes a wide
varietyofproductscalledasadipocytokines[157].Duetothe
fact that a substantial proportion of women with PCOS are
overweight, many are obese and some are extremely obese,
the genes of the most popular adipocytokines such as leptin
and adiponectin have been investigated as candidate genes in
the pathogenesis of PCOS.
Oksanen et al. sequenced the leptin gene in a small
group of PCOS patients, but failed to detect any muta-
tions of the coding exons [158]. In this study, the investi-
gators also sequenced the leptin receptor gene and found
previously identiﬁed amino acid variants in exons 2, 4,
and 12 as well as the pentanucleotide insertion in the 3 -
u n t r a n s l a t e dr e g i o n[ 158]. However, the allele frequencies of
these polymorphisms did not diﬀer fromthose in the general
population [158].
After the sequence polymorphisms of adiponectin gene
identiﬁedinhumans,moststudieshavefocusedontwopoly-
morphisms, T45G in exon 2 and G276T in intron 2. It was
demonstrated consistently that these polymorphisms asso-
ciate with obesity, insulin resistance, and the risk of type-
2 diabetes [159–162]. In a study assessing the association
of PCOS with 15 genomic variants previously described to
inﬂuence insulin resistance, obesity, and/or type-2 diabetes
mellitus, San Mill´ an et al. failed to ﬁnd any association be-
tween PCOS and these two common polymorphisms of the
adiponectin gene [163]. Concurrently, Panidis et al. investi-
gated the possible association of the T45G adiponectin gene
polymorphisms with PCOS [164]. Although the frequency
of GG, TT, and TG genotypes were similar between women
with PCOS and controls, when the frequencies of GG and
TG genotypes assessed together, a signiﬁcant diﬀerence was
observed between the groups [164]. This study reported no
signiﬁcantrelationbetweentheT45Gadiponectingenepoly-
morphism and circulating adiponectin levels, obesity, and
the metabolic features of PCOS; however, it was observed
that the carriers of the G allele had a tendency for lower
serum adiponectin levels in PCOS group [164]. More re-
cently, two diﬀerent studies from Greece [165]a n dS p a i n
[166] rebutted the probability that the T45G and G276T
polymorphisms of adiponectin gene could be associated with
PCOS.Additionally,thesestudiesreportedtheconﬂictingre-
sults about eﬀects of these SNPs on adiponectin and hor-
monal variables [165, 166].
Taken together these data suggest that, diﬀerent from the
other insulin resistant disorders; the adiponectin gene seems
not to play a causative role in the pathogenesis of PCOS.
However, the polymorphisms of the adiponectin gene may,
at least in part, have a role in the phenotypic variability of
PCOS.
4.5.2. PPAR-γ gene
PPAR-γ is a transcription factor involved in adipogenesis,
energy metabolism and a functional receptor for thiazo-
lidinediones (TZDs) introduced as insulin-sensitizing agents
[167]. Additionally, PPAR-γ gene (PPAR-γ) l o c a t e do n3 p 2 5
[168] is a candidate gene for the regulation of adipose tissue
metabolism in humans and also a susceptibility gene for the
development of both obesity and diabetes [169–171]. PPAR-
γ agonists, namely TZDs, currently oﬀer an eﬀective treat-
ment option for the management of patients with type-210 PPAR Research
diabetes. Since PCOS and type-2 diabetes share certain phe-
notypic features such as obesity and insulin resistance, sev-
eral studies investigated the potential therapeutic eﬀects of
TZDs on the ovulatory dysfunction, hirsutism, hyperandro-
genism and insulin-resistance of PCOS. The vast majority of
these clinical trials reported positive results [172–174].
Studies of rare mutations and frequent polymorphisms
of PPAR-γ have facilitated to improve our knowledge on the
biological roles of PPAR-γ and its implication in diseases.
There are two PPAR-γ gene polymorphisms that have been
thoroughly investigated in various populations (reviewed
in [175]). The ﬁrst is the silent CAC478-CAT substitution
which resides in the exon 6 and the second is a proline to
alanine missense variant at the codon 12 of the exon 2. Stud-
ies assessing the potential impact of PPAR-γ gene on PCOS
are discussed below and summarized in Table 3.
In the ﬁrst study, Urbanek et al. found no evidence for
any linkage or association with PCOS for a marker close to
the PPAR-γ gene [35]. In another study, Hara et al. showed
that Caucasian PCOS patients with Pro/Ala alleles are more
insulin sensitive than those with Pro/Pro [176]. Recently,
Hahn et al. also reported that the Pro12Ala polymorphism
of PPAR-γ are associated with increased insulin sensitivity
as well as lower hirsutism scores in PCOS women [177].
Afterwards, in accordance with these data, Tok et al. re-
ported that carriers of this polymorphism were less insulin-
resistant than the Pro12Ala-negative controls and patients
with PCOS. The diﬀerence between the groups for carry-
ing the polymorphism did not reach signiﬁcance, probably
due to very small sample size [178]. In addition, Korhonen
et al. from Finland investigated the Pro12Ala polymorphism
in patients with PCOS and demonstrated that the frequency
of the variant Ala isoform was reduced with a slight signif-
icance in the PCOS group [179]. Furthermore, Yilmaz et
al. examined the impact of the Pro12Ala polymorphism on
insulin resistance in the ﬁrst-degree relatives of subjects with
PCOS. They found that the frequency of the variant Ala iso-
form was signiﬁcantly reduced in the ﬁrst-degree relatives of
PCOS subjects compared to the controls and also demon-
strated that the ﬁrst-degree relatives of PCOS subjects with
the Pro12Ala polymorphism were less insulin resistant than
the ﬁrst-degree relatives of PCOS subjects with the Pro12Pro
polymorphism [180]. The latter group, in a more recent
study, examined the relationship between the Pro12Ala poly-
morphism and the clinical and hormonal characteristics in
women with PCOS. When PCOS subjects with the Pro allele
and the Ala allele of PPAR-γ were compared, they found that
having the Ala allele of this nuclear receptor gene was related
with reduced androgen levels, a lower Ferriman-Gallwey
score, a lower insulin resistance index, a lower body mass
index, and a lower waist-to-hip ratio [181]. However, this
type of polymorphism was not found to be associated with
PCOS in women from Spain [163], Italy [182] and China
[183]. Additionally, in two diﬀerent studies, Orio et al. have
investigated the impact of PPAR-γ gene polymorphisms in
PCOS pathogenesis. First, they studied the exon-6 C142T
allele of PPAR-γ and showed a higher frequency in Italian
women with PCOS compared to the controls [182]. Subse-
quently, they investigated the putative inﬂuence of PPAR-γ
gene Pro12Ala polymorphism on the adiponectin levels in
PCOS patients and in healthy women. However, they failed
to demonstrate any eﬀect of Pro12Ala polymorphism on
adiponectin levels in neither group [184].
The limited size of the study populations and the low
stringency in diagnostic criteria are the limitations of the
genetic association studies seeking for the relevance of the
PPARg gene with PCOS and thus, should be interpreted cau-
tiously. Likewise, the lack of a clear-cut association to the
polymorphisms does not rule out the implications of PPARg
on the pathogenesis of PCOS. Even though genetic associa-
tion studies do not clearly establish any link between PCOS
and PPAR-γ polymorphisms, functional investigations still
point out the suspicious role of PPAR-γ on PCOS. Seto-
Young et al. demontrated that PPAR-γ ligands stimulate the
steroidogenesisonhumanovariansteroidogenictissue[191].
Pioglitazone treatment increased growth hormone secretion
and stimulated levels in PCOS patients in a randomized trial
[192]. Authors comment that this action might be a func-
tion of improved insulin sensitivity [192]. While these func-
tional studies implicate the relevance of PPAR-γ function to
PCOS, the molecular mechanisms to explain the beneﬁcial
action of PPAR-γ activators on the clinical picture of PCOS
arestillobscure.Thiseﬀectmaybeaconsequenceofpotenti-
ating the insulin sensitivity on the periphery and the gonads
[192]. Jansen et al. employed a more mechanistic approach
and compared the gene expression proﬁles in PCOS ovaries
to control subjects and female to male transsexuals [193].
These authors draw special attention on the diﬀerentiation
promoting eﬀect and interplay between the histon deacety-
lase (HDAC) function and the PPAR-γ gene [193]. Interest-
ingly the antiepileptic drug valproic acid has both HDAC
inhibitory activity and PPAR-γ agonist action that create a
condition that resembles the PCOS picture during adminis-
tration [194]. As a consequence, further functional studies
are required to elucidate the transcriptional cascade and the
events that link PPAR-γ function to PCOS pathogenesis.
4.6. Genesinvolvedinchronicinﬂammation
Chronic inﬂammation appears to play a role in the devel-
opment of insulin resistance (Figure 1) and cardiovascular
disease [195] and it might be involved in the pathogenesis
of PCOS [196] although not all agree [189]. Some genomic
variants related to inﬂammation have been studied in PCOS.
4.6.1. TNF-α
Tumor necrosis factor (TNF)-α is cytokine secreted by adi-
pose tissue that plays an important role in insulin resis-
tance [197]. The variants that are studied up to date are
−308 G/A [185, 186, 198], −1196 C/T, −1125 G/C, −1031
T/C, −863 C/A, −857 C/T, −316 G/A, −238 G/A, −163 G/A
[198], and −850 C/T [187]. The polymorphisms in the TNF-
α gene do not seem to have a key role in the pathogenesis
of PCOS. In a study by Escobar-Morreole et al., the carri-
ers of −308 A alleles showed increased serum androgen andUgur Unluturk et al. 11
Table 2: Summary of the studies of candidate genes in PCOS.
Gene Locus/variant Subjects/phenotypic trait (a)Assoc. References
Genes involved in ovarian and adrenal steroidogenesis
CYP11a
(tttta)n
PCOS/
hyperandrogenemia Yes Gharani et al. [29]
PCOS/
body mass index Yes Wang et al. [31]
PCOS/
hyperandrogenemia Yes Diamanti-Kandarakis et al. [30]
D15S519
D15S520
PCOS/
hyperandrogenemia No Urbanek et al. [35]
(tttta)n
Hirsutism/
hyperandrogenism No San Mill´ an et al. [36]
(tttta)n
PCOS/
hyperandrogenemia No Tan et al. [33, 34]
D15S520,1500bp to
D15S520
PCOS, (b)PCO/
testosterone levels No Gaasenbeek et al. [32]
CYP21 Heterozygosity for
CYP21 mutations
Premature pubarche/
hyperandrogenism Yes Witchel et al. [39]
Hyperandrogenism Yes Witchel et al. [40]
Hirsutism/
origin of androgen excess No Escobar-Morreale et al. [41]
Hirsutism, PCOS/
adrenal hyperresponsiveness No Glintborg et al. [42]
PCOS/
hyperandrogenemia No Witchel et al. [43]
CYP17
−34T/C (c)SNP
PCOS Yes Carey et al. [52]
PCOS/
hyperandrogenemia Yes Diamanti-Kandarakis et al. [53]
PCOS/
hyperandrogenemia No Gharani et al. [54]
PCOS/
hyperandrogenemia No Techatraisak et al. [55]
PCOS/
hormone proﬁle No Marszalek et al. [57]
Mutation scanning/
no mutation
Mild
hyperandrogenism No Witchel et al. [56]
D10S192 PCOS No Urbanek et al. [35]
T/C substitution in
the 5  (d)PR
PCOS/
(e)DHEAS levels No Kahsar-Miller et al. [58]
CYP19
CYP19 PCOS No Urbanek et al. [35]
(tttta)n/D15S103 PCOS No Gharani et al. [29]
Aromatase SNP 50
genotype Aromatase
distal promoter
region variation
PCOS symptom score
testosterone
concentrations
Yes Petry et al. [74, 75]12 PPAR Research
Table 2: Continued.
Gene Locus/variant Subjects/phenotypic trait Assoc. References
Genes involved in steroid hormone eﬀects
AR AR PCOS No Urbanek et al. [35]
SHBG gene
AR (CAG)n
PCOS/infertile and
fertile women No Mifsud et al. [83]
PCOS/infertility Yes Hickey et al. [84]
PCOS/(f)BMI,
testosterone levels No J¨ a¨ askel¨ ainen et al. [85]
(TAAAA)n PCOS/SHBG levels Yes Xita et al. [90]
Asp327Asn Hirsutism/SHBG levels Yes Cousin et al. [91]
D17S1353 PCOS No Urbanek et al. [35]
Genes involved in gonadotropin action and regulation
LHβ
Trp8Arg; Ilg15Thr
PCOS/higher frequency of
the SNPs in obese PCOS Yes Rajkhowa et al. [98]
PCOS/lower frequency of
the SNPs in obese PCOS Yes Tapanainen et al. [99]
Menstrual disorders No Ramanujam et al. [100]
Ser102 Gly Menstrual disorders Yes Ramanujam et al. [100]
Trp8Arg; Ilg15Thr PCOS No Elter et al. [101]
Several SNPs Ovulatory disorders
including PCOS Yes Takahashi et al. [103]
Follistatin gene
D5S474
D5S623
D5S822
PCOS Yes Urbanek et al. [35]
Mutation scanning/
variants at 17 sites PCOS No Urbanek et al. [110]
Mutation scanning/
no mutation PCOS No Liao et al. [111]
Mutation scanning/
no mutation except
G951A (silent mutation)
PCOS/hormone proﬁle No Calvo et al. [112]
Genes involved in insulin action and secretion
INS INS VNRT
PCOS/premature male
pattern baldness Yes Waterworth et al. [123]
PCOS Yes Eaves et al. [124]
PCOS/insulin resistance
and hyperandrogenemia Yes Michelmore et al. [125]
PCOS/
hyperandrogenemia No Urbanek et al. [35]
Hyperandrogenemia No Calvo et al. [126]
PCOS/insulin
secretion and action No Vankova et al. [127]
PCOS; PCO;
testosterone level No Powell et al. [129]Ugur Unluturk et al. 13
Table 2: Continued.
Gene Locus/variant Subjects/phenotypic trait Assoc. References
INSR
Mutation scanning PCOS/insulin resistance No Talbot et al. [133]
D19S884
PCOS Border Urbanek et al. [35]
PCOS Yes Tucci et al. [134]
PCOS No Villuendas et al. [135]
PCOS Yes Urbanek et al. [136]
C10923T PCOS/lean subjects Yes Siegal et al. [137]
IRS
IRS1 PCOS No Urbanek et al. [35]
Gly972Arg (IRS1) PCOS Yes Sir-Petermann et al. [142]
Gly972Arg (IRS1)
Gly1057Asp(IRS2) PCOS/insulin resistance Yes El-Mkadem et al. [143]
IRS
Gly972Arg (IRS1) PCOS/insulin and
glucose levels No Ehrmann et al. [144]
Gly972Arg (IRS1)
Gly1057Asp(IRS2)
PCOS/glucose
homeostasis No Villuendas et al. [145]
Gly972Arg (IRS1)
PCOS/insulin resistance,
and obesity Yes Dilek et al. [146]
PCOS/insulin resistance,
hormone proﬁle, and
metformin eﬀects
Yes Ertunc et al. [147]
CAPN10
UCSNP-19, -43, and -63 PCOS/insulin levels Yes Ehrmann et al. [152]
UCSNP-19, -43, -44,
and -63
PCOS Yes Gonzales et al. [153, 154]
PCOS/insulin levels No Haddad et al. [155]
UCSNP-43 Hirsutism/hirsutism score Yes Escobar-Morreale et al. [156]
UCSNP-44
Hirsutism/PCOS,
idiopathic hirsutism, and
hyperandrogenism
No Escobar-Morreale et al. [156]
UCSNP-45 Hirsutism/idiopathic
hirsutism Yes Escobar-Morreale et al. [156]
Genes involved in energy homeostasis
Leptin gene &
Leptin receptor
Mutation scanning of
the leptin gene;
polymorphism in
leptin receptor gene
PCOS/obesity No Oksanen et al. [158]
Adiponectin gene
T45G in exon 2
G276T in intron 2 PCOS No San Mill´ an et al. [163]
T45G in exon 2 PCOS No Panidis et al. [164]
T45G in exon 2
G276T in intron 2
PCOS No Xita et al. [165]
PCOS No Escobar-Morreale et al. [166]
Genes involved in chronic inﬂammation
TNF-α −308 G/A
PCOS No Milner et al. [185]
PCOS No Mao et al. [186]
PCOS No Korhonen et al. [187]14 PPAR Research
Table 2: Continued.
Gene Locus/variant Subjects/phenotypic trait Assoc. References
TNFR2 gene Met196Arg PCOS/
hyperandrogenism Yes Peral et al. [188]
IL-6 −174 G/C PCOS Yes Mohlig et al. [189]
IL-6 signal
transducer gp 130 Gly148Arg PCOS/
hyperandrogenism Yes Escobar-Morreale et al. [190]
IL-6 receptor-α CA repeats PCOS/obesity, and
Hyperandrogenism Yes Escobar-Morreale et al. [190]
(a)Assoc.: association.
(b)PCO: polycystic ovaries.
(c)SNP: single nucleotide polymorphism.
(d)PR: promoter region.
(e)DHEAS: dehydroepiandrosterone sulfate.
(f)BMI: body mass index.
Table 3: Genes involved in energy homeostasis: PPAR-γ.
Gene Locus/variant Subjects/phenotypic trait (a)Assoc. References
PPAR-γ
Gene
D3S1263 PCOS No Urbanek et al. [35]
Pro12Ala
PCOS/reduced insulin resistance Yes Hara et al. [176]
PCOS/lower hirsutism scores,
increased insulin sensitivity Yes Hahn et al. [177]
Reduced insulin resistance (b) Yes Tok et al. [178]
PCOS Yes Korhoren et al. [179]
PCOS No San Mill´ an et al. [163]
PCOS No Orio et al. [182]
PCOS/clinical and hormonal
characteristics Yes Yilmaz et al. [181]
CAC478CAT PCOS/obesity, leptin levels Yes Orio et al. [182]
PPAR-γ &
PGC-1α
Pro12Ala &
Gly482Ser PCOS No Wang et al. [183]
(a)Assoc.: association. (b) No statistical signiﬁcance.
17-hydroxyprogesterone levels before and after stimulation
with the GnRH analogue leuprolide [198]. These ﬁndings
may indicate that TNF-α gene polymorphism might be a
modifying factor for phenotypic traits.
Other genes involved in chronic inﬂammation, such as
TNFR2 (type-2 TNF receptor) gene [188], IL-6 [189, 199],
IL-6 signal transducer gp 130 [190], IL-6 receptor [190]g e n e s
have also been investigated as a candidate gene for pathogen-
esis of PCOS. The results of these candidate gene studies and
those discussed above are summarized in Table 2.
4.7. Othergenes
4.7.1. Plasminogenactivatorinhibitor-1gene
Patients with PCOS cluster cardiovascular risk factors [6].
Abnormalities in the coagulation and ﬁbrinolytic pathways
contribute to the development of CVD in PCOS [200].
Elevated plasminogen activator inhibitor-1 (PAI-1) levels are
associated with increased cardiovascular risk and increased
thrombogenic tendency, and in general, women with PCOS
also have an increased activity of PAI-1 [6]. The 4G/5G poly-
morphism in the promoter region of the PAI-1 is associated
with increased plasma PAI-1 concentrations in patients with
type-2 diabetes and myocardial infarction [201]. In order to
understand the role of the PAI-1 polymorphism in PCOS
patients, Diamanti-Kandarakis et al. investigated this poly-
morphism in Greek women with PCOS and found a higher
frequency of the 4G/4G and 4G/5G genotypic subtypes in
PCOScomparedwithcontrols[202].Theseinvestigatorsalso
reported that PCOS women have higher levels of PAI-1 and
that the presence of the 4G allele in the PAI-1 promoter re-
gion of the gene further increases the PAI-1 levels [202].
In addition to the genes mentioned above in detail, many
diﬀerentgenessuchasHSD3B2[35,203],17α-hydroxysteroid
dehydrogenases [35, 204], dopamine receptor [205, 206], IGFUgur Unluturk et al. 15
Table 4: Major limitations of genetic studies in PCOS.
Lack of universally accepted diagnostic
criteria and deﬁnition
• NICHD criteria
• Ultrasonographic criteria
• Rotterdam criteria
Male phenotype?
• Premature baldness
• Increased pilosity
• Increased DHEAS levels?
• Exaggerated responses to GnRH and ACTH
• Insulin resistance, glucose intolerance
Relatively small sample size of the
study populations
• Potential statistical error
Aﬀected reproduction • Diﬃculty in studying more than one generation
Nonrandom ascertainment of families • Bias?
Obscurity in the mode of inheritance
• Autosomal Dominant [8, 12]
• Monogenic [14, 17]
• X-Linked [9, 10]
Variable penetrance and expressivity
• Diﬃculty in assignment of the phenotype
(aﬀected versus unaﬀected)
Locus heterogeneity • Summarized in Section 4.
Environmental interactions • Compensatory adaptation?
[35, 163], aldosterone synthetase [207], paraoxonase [163],
glycogen synthetase [208], resistin [209], apoprotein E [210]
h a v eb e e ns t u d i e du pt od a t ei nav a r i e t yo fP C O Sp o p u l a -
tions. Similar to the studies described in detail above, either
negative or controversial results have been obtained.
5. LIMITATIONS AND CHALLENGES FOR GENETIC
STUDIES IN PCOS
PCOS is a common and complex disorder. Similar to
other complex traits such as type-2 diabetes and obesity,
the complexity of the underlying genetic model as well
as potential gene-gene and gene-environment interactions
pose a diﬃculty for genetic analyses. Major limitations and
challenges in the genetic studies of PCOS are shown in
Table 4.
5.1. Issuesrelatedtophenotypeandgenotype
Thereareseveralmajorlimitationsrelevanttothephenotype
and genotype studies of PCOS. Firstly, there has been an on-
going debate for the deﬁnition of and the diagnostic criteria
for PCOS, and diﬀerent diagnostic criteria used in diﬀerent
studies introduce complexity into the comparison of the re-
sults [211]. Secondly, how to assign aﬀected status of men in
PCOS families remains obscure although several clinical and
biochemical characteristics have been suggested for the male
phenotype including premature baldness, increased pilosity,
increased DHEAS levels, exaggerated responses to GnRH or
ACTH, and insulin resistance and glucose intolerance [109].
Thirdly,relativelysmallsamplesizesofthestudypopulations
might result in statistical errors in population-based genetic
studies of association for unrelated cases and controls [212].
Linkage studies run on large families spanning at least
three generations including more than one aﬀected and un-
aﬀected individuals are successful for the identiﬁcation of a
susceptibility locus. As infertility is one of the primary man-
ifestations of PCOS, this is the most important fact which
limits the availability of large pedigrees. In addition, nonran-
dom assignment of families increases the potential for selec-
tion bias. We should also note that since the mode of inheri-
tance expressivity and penetrance is obscure, it is diﬃcult to
assess if one individual is aﬀected or unaﬀected. Moreover,
comparison of one pedigree to another may also harbor ob-
stacles due that PCOS appears to be a highly heterogeneous
disorder, with locus and allelic heterogeneity both between
and within families likely.
5.2. Environmentalfactorsandcompensatory
adaptation
The impact of environmental factors for the development
of PCOS is currently an active area of research. One im-
portant point is that the compensatory adaptations achieved
in the intrauterine life might be associated with PCOS later
in life (reviewed by Escobar-Morreale [213] ) .T h e r ei sar e -
cent evidence from animal studies that metabolic compen-
satory adaptations of carbohydrate metabolism and insulin
signaling acquired in the intrauterine life is carried on to the
postnatal life [214]. This intrauterine compensatory adapta-
t i o nm i g h ta sw e l lb ei m p l i c a t e db ye p i g e n e t i cf a c t o r ss u c ha s
DNA methylation.16 PPAR Research
6. CONCLUSIONSAND FUTURE PERSPECTIVES
Based on familial, metabolic, and endocrine data, PCOS can
be taken as a complex genetic trait similar to type-2 diabetes
and obesity. It appears that there are multiple inherited, en-
vironmentaloracquiredfactorsthatmayincreasetheriskfor
developing PCOS. The eﬀorts to identify the genes and mu-
tations predisposing to PCOS up to date have been primar-
ily based on association and linkage studies with functional
candidate genes only a few of which exhibited signiﬁcant ev-
idence of association with PCOS. Furthermore, most of the
positive ﬁndings obtained with PCOS phenotypes have not
been replicated in more than one population. These results
are not surprising considering that genes with such a great
impact on the phenotype are not expected to be responsible
for PCOS. However, it is important to emphasize that rela-
tively small sample size of study populations is a major limi-
tation for most of the studies.
Identiﬁcation of the candidate genes and understand-
ing of their function holds the promise for the establish-
ment of the speciﬁc molecular basis for PCOS. More studies
with larger sample sizes on diﬀerent populations are needed
to determine whether suggested functional candidate genes
play any role at all in the etiology of PCOS. Two recent ad-
vances in genetics, namely genome-wide scan approach and
the HapMap project, will serve as tools for both identiﬁca-
tion of novel loci and narrowing the known genomic regions
for PCOS. The acquisition of genetic information regarding
PCOS will be most useful for providing new insights into the
pathophysiology of the syndrome and will eventually have a
profound eﬀect on the clinical management of the PCOS pa-
tients.
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